A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system
- PMID: 9412880
- DOI: 10.1016/s1053-0770(97)90116-6
A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system
Abstract
Objectives: To examine pump-prime aprotinin action on coagulation and fibrinolysis in patients undergoing primary coronary revascularization.
Design: A prospective randomized study.
Setting: A university hospital.
Participants: Forty-three patients were randomly assigned to either group A, 21 patients treated with 2 x 10(6) kallikrein inhibitor units (KIU) of aprotinin in the cardiopulmonary bypass (CPB) prime, or group B, 22 patients, untreated.
Interventions: Patients, scheduled for elective coronary surgery, were treated with 2 x 10(6) KIU of aprotinin in the CPB prime. Markers of coagulation and fibrinolysis were evaluated.
Measurements and main results: Surgical times, number of reopenings, and allogeneic blood requirements were collected for each patient. Blood samples were obtained before and after surgery for assessing coagulation (prothrombin time [PT], activated partial thromboplastin time [aPTT], ethanol test, factor VII, antithrombin III [AT III], thrombin-antithrombin III complex [TAT], fragment 1.2 of prothrombin [F1.2]) and fibrinolysis (fibrin degradation products [FOP], plasmin-antiplasmin complexes [PAP], D-dimers) markers variations. In group A surgical times were faster, there were fewer reopenings (0 v 3), and fewer blood transfusions (1 patient v 4 patients). The two groups did not differ for PT, aPTT, and fibrinogen measurements. Postoperative FDP (measurable in more patients of group B at the end of the operation), PAP, and D-dimers postoperatory levels (less increased in aprotinin group) show the antifibrinolytic properties of the drug. Regarding the coagulation markers, factor VII decreased, whereas TAT and F1.2 increased, all to a lesser extent in the aprotinin group compared with the untreated patients, at the end of operation.
Conclusion: Pump-prime aprotinin minimized, even if not completely inhibited, the activation of coagulation and fibrinolysis during CPB, possibly ensuring a less complicated and safer postoperative recovery. It seemed to allow the maintenance of a correct balance of hemostatic systems, avoiding the risk of thrombotic phenomena.
Similar articles
-
Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. Groningen Lung Transplant Group.J Thorac Cardiovasc Surg. 1996 Sep;112(3):599-606. doi: 10.1016/s0022-5223(96)70041-7. J Thorac Cardiovasc Surg. 1996. PMID: 8800145
-
Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.Anesth Analg. 2004 Feb;98(2):285-290. doi: 10.1213/01.ANE.0000096260.35340.C5. Anesth Analg. 2004. PMID: 14742356 Clinical Trial.
-
Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.Ann Thorac Surg. 1993 May;55(5):1205-9. doi: 10.1016/0003-4975(93)90035-g. Ann Thorac Surg. 1993. PMID: 7684219 Clinical Trial.
-
Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.Ann Thorac Surg. 1998 Jun;65(6 Suppl):S45-50; discussion S50-1, S74-6. doi: 10.1016/s0003-4975(98)00330-0. Ann Thorac Surg. 1998. PMID: 9647138 Review.
-
Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?J Cardiovasc Pharmacol. 1996;27 Suppl 1:S50-7. doi: 10.1097/00005344-199600001-00011. J Cardiovasc Pharmacol. 1996. PMID: 8938284 Review.
Cited by
-
Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*).J Res Med Sci. 2012 Jan;17(1):74-82. J Res Med Sci. 2012. PMID: 23248660 Free PMC article.
-
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD001886. doi: 10.1002/14651858.CD001886.pub4. Cochrane Database Syst Rev. 2011. PMID: 21412876 Free PMC article.
-
Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.Drugs. 1999 Feb;57(2):233-60. doi: 10.2165/00003495-199957020-00015. Drugs. 1999. PMID: 10188764 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials